4:36 PM
 | 
Jul 05, 2013
 |  BC Extra  |  Company News

UCB licenses olokizumab to R-Pharm

UCB Group (Euronext:UCB) granted R-Pharm CJSC (Moscow, Russia) exclusive, worldwide rights to develop and commercialize olokizumab, a humanized mAb against IL-6. UCB received an undisclosed upfront payment and is eligible for undisclosed milestones, plus royalties. Last September, UCB...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >